MX2008011141A - Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas. - Google Patents

Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas.

Info

Publication number
MX2008011141A
MX2008011141A MX2008011141A MX2008011141A MX2008011141A MX 2008011141 A MX2008011141 A MX 2008011141A MX 2008011141 A MX2008011141 A MX 2008011141A MX 2008011141 A MX2008011141 A MX 2008011141A MX 2008011141 A MX2008011141 A MX 2008011141A
Authority
MX
Mexico
Prior art keywords
e2his
csfv
further characterized
vaccine antigen
chimeric
Prior art date
Application number
MX2008011141A
Other languages
English (en)
Spanish (es)
Inventor
Nunez Lazaro Hiram Betancourt
Serra Lila Rosa Castellanos
Negrin Yasser Perera
Lopez Luis Javier Gonzalez
Rodriguez Silvio Ernesto Perea
Castro Boris Ernesto Acevedo
Ulloa Arielis Rodriguez
Valdes Jeovanis Gil
Gomez Yassel Ramos
Puente Aniel Sanchez
De Cossio Dorta Duque Jorge Fernandez
Perez Vladimir Besada
Daniel Fernando Alonso
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008011141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2008011141A publication Critical patent/MX2008011141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2008011141A 2006-02-28 2007-02-28 Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas. MX2008011141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
PCT/CU2007/000010 WO2007098719A1 (es) 2006-02-28 2007-02-28 Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Publications (1)

Publication Number Publication Date
MX2008011141A true MX2008011141A (es) 2009-01-26

Family

ID=40134932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011141A MX2008011141A (es) 2006-02-28 2007-02-28 Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas.

Country Status (23)

Country Link
US (3) US8871725B2 (US20060241273A1-20061026-C00009.png)
EP (1) EP1997506B8 (US20060241273A1-20061026-C00009.png)
JP (2) JP5733880B2 (US20060241273A1-20061026-C00009.png)
KR (1) KR101454866B1 (US20060241273A1-20061026-C00009.png)
CN (1) CN101432012B (US20060241273A1-20061026-C00009.png)
AR (1) AR059645A1 (US20060241273A1-20061026-C00009.png)
AU (1) AU2007219572B2 (US20060241273A1-20061026-C00009.png)
BR (1) BRPI0708307B1 (US20060241273A1-20061026-C00009.png)
CA (1) CA2642943C (US20060241273A1-20061026-C00009.png)
CL (1) CL2015001086A1 (US20060241273A1-20061026-C00009.png)
CU (1) CU23511B6 (US20060241273A1-20061026-C00009.png)
CY (1) CY1114686T1 (US20060241273A1-20061026-C00009.png)
DO (1) DOP2007000040A (US20060241273A1-20061026-C00009.png)
HK (1) HK1132451A1 (US20060241273A1-20061026-C00009.png)
MX (1) MX2008011141A (US20060241273A1-20061026-C00009.png)
MY (1) MY150135A (US20060241273A1-20061026-C00009.png)
NO (1) NO341904B1 (US20060241273A1-20061026-C00009.png)
PE (1) PE20081191A1 (US20060241273A1-20061026-C00009.png)
PL (1) PL1997506T3 (US20060241273A1-20061026-C00009.png)
RU (1) RU2396974C2 (US20060241273A1-20061026-C00009.png)
UY (1) UY30175A1 (US20060241273A1-20061026-C00009.png)
WO (1) WO2007098719A1 (US20060241273A1-20061026-C00009.png)
ZA (1) ZA200807323B (US20060241273A1-20061026-C00009.png)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA3116731A1 (en) 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN109875998B (zh) * 2019-01-24 2021-09-03 武汉大学 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物
CN110448699B (zh) * 2019-06-12 2022-03-11 天津医科大学 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
US20060014987A1 (en) * 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
TR200808208T1 (tr) * 2003-12-09 2008-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Also Published As

Publication number Publication date
JP5733880B2 (ja) 2015-06-10
UY30175A1 (es) 2008-01-31
US20150111832A1 (en) 2015-04-23
CA2642943A1 (en) 2007-09-07
PL1997506T3 (pl) 2013-04-30
RU2008138534A (ru) 2010-04-10
US20090130228A1 (en) 2009-05-21
NO20084119L (no) 2008-11-25
CN101432012B (zh) 2013-01-02
CY1114686T1 (el) 2016-10-05
RU2396974C2 (ru) 2010-08-20
NO341904B1 (no) 2018-02-19
US9226946B2 (en) 2016-01-05
BRPI0708307B8 (US20060241273A1-20061026-C00009.png) 2021-05-25
JP2009528306A (ja) 2009-08-06
EP1997506B1 (en) 2012-12-05
BRPI0708307B1 (pt) 2019-07-23
KR20090030251A (ko) 2009-03-24
US8871725B2 (en) 2014-10-28
MY150135A (en) 2013-11-29
KR101454866B1 (ko) 2014-11-04
CL2015001086A1 (es) 2016-05-13
US20150030700A1 (en) 2015-01-29
WO2007098719A1 (es) 2007-09-07
EP1997506B8 (en) 2013-02-20
AU2007219572B2 (en) 2012-07-05
EP1997506A1 (en) 2008-12-03
PE20081191A1 (es) 2008-09-24
BRPI0708307A2 (pt) 2011-05-24
US9278118B2 (en) 2016-03-08
CA2642943C (en) 2013-07-23
ZA200807323B (en) 2009-05-27
AU2007219572A1 (en) 2007-09-07
CN101432012A (zh) 2009-05-13
HK1132451A1 (en) 2010-02-26
JP2013231065A (ja) 2013-11-14
CU23511B6 (es) 2010-04-13
DOP2007000040A (es) 2007-09-30
AR059645A1 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
JP7445375B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
JP2738524B2 (ja) ウイルスに感染した動物とワクチン接種した動物を区別する方法
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
MX2008011141A (es) Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas.
TW201026850A (en) PCV 2-based methods and compositions for the treatment of pigs
DE69934583T2 (de) Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
HUT55243A (en) Process for producing recombinant subunite vaccine against pseudolyssa
JP2006524224A (ja) ウシの繁殖疾患を防止する方法
CA2638830C (en) Chimeric vaccine antigens against classical swine fever virus
US11529407B2 (en) Isolation of a novel pestivirus causing congenital tremor A
Toussaint et al. Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8
EP0389034B1 (en) Hog cholera virus vaccine and diagnostic
CN109195624B (zh) Hev疫苗
JP2024514197A (ja) 仮性狂犬病ウイルスワクチン
EP0471457A2 (en) Herpesvirus-based viral vector which expresses a foot & mouth disease virus epitope
JP2905483B2 (ja) 弱毒化ヘルペスウイルス及び外来性ｄｎａを含むヘルペスウイルス
JP2021516551A (ja) Ｅｈｖ挿入部位ｕｌ４３
RU2765658C9 (ru) Выделение нового пестивируса, вызывающего врожденный тремор а
Shoup Studies of active and passive immunity using a baculovirus-expressed transmissible gastroenteritis virus (TGEV) s glycoprotein vaccine in swine and development of an immunohistochemical assay to detect TGEV antigens

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights